Therapeutic Applications for Oncolytic Self-Replicating RNA Viruses

Area of Science:

• Virology
• Molecular Biology
• Oncology

Background:

• Self-replicating RNA viruses are emerging as potent delivery systems for gene therapy.
• Their ability to replicate within host cells allows for higher transgene expression compared to synthetic mRNA.
• Various RNA virus families, including alphaviruses, flaviviruses, measles viruses, and rhabdoviruses, are explored for therapeutic use.

Purpose of the Study:

• To review the therapeutic potential of self-replicating RNA viruses.
• To highlight their application in cancer therapy, particularly as oncolytic viruses.
• To summarize evidence from preclinical and clinical studies.

Main Methods:

• Review of literature on self-replicating RNA viruses for therapeutic applications.
• Analysis of studies utilizing alphaviruses, flaviviruses, measles viruses, and rhabdoviruses.
• Examination of preclinical data and clinical trial results for oncolytic RNA virus therapy.

Main Results:

• Self-replicating RNA viruses facilitate high transgene expression and reduced dosage requirements.
• Oncolytic RNA viruses engineered for tumor-specific replication show therapeutic efficacy in animal models.
• Clinical trials indicate safety and positive outcomes, including T-cell responses, tumor antigen responses, complete remission, and improved survival.

Conclusions:

• Self-replicating RNA viruses represent a promising platform for developing advanced therapeutics.
• Oncolytic RNA viruses have demonstrated significant potential in cancer treatment, supported by clinical evidence.
• Further research and clinical application of these viral vectors are warranted.